Literature DB >> 11414548

Comorbidity in generalized anxiety disorder: impact and implications.

D J Stein1.   

Abstract

Studying comorbidity may be particularly useful in shedding light on the nature, course, and management of generalized anxiety disorder (GAD). This article reviews the common comorbidities in GAD, their impact on functioning and on medical utilization, and their implications for treatment. Comorbidity in this area is complex in that GAD may be primary (predating other illnesses) or secondary (following other conditions). Nevertheless, studies demonstrate the high prevalence of patients with a matrix of anxious-somatic-depressive symptoms and show that GAD comorbidity is associated with both increased disability and increased medical utilization. Clinical implications of this work include the need for rigorous assessment of anxiety, somatic, and depressive symptoms in patients who present with any one of these sets of complaints and the possibility that early treatment of GAD may be critical in preventing subsequent morbidity.

Entities:  

Mesh:

Year:  2001        PMID: 11414548

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  17 in total

1.  The characteristics of anxiety and depression symptom severity in older adults living in public housing.

Authors:  Adam Simning; Yeates Conwell; Susan G Fisher; Thomas M Richardson; Edwin van Wijngaarden
Journal:  Int Psychogeriatr       Date:  2011-10-21       Impact factor: 3.878

Review 2.  Current considerations in the treatment of generalized anxiety disorder.

Authors:  Martin A Katzman
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

3.  Screening for Generalized Anxiety Disorder in inpatient psychosomatic rehabilitation: pathological worry and the impact of depressive symptoms.

Authors:  Simone Salzer; Christian Stiller; Achim Tacke-Pook; Claus Jacobi; Eric Leibing
Journal:  Psychosoc Med       Date:  2009-07-09

4.  Protocol for a randomised controlled trial investigating the effectiveness of an online e-health application compared to attention placebo or sertraline in the treatment of generalised anxiety disorder.

Authors:  Helen Christensen; Adam J Guastella; Andrew J Mackinnon; Kathleen M Griffiths; Claire Eagleson; Philip J Batterham; Kanupriya Kalia; Justin Kenardy; Kylie Bennett; Ian B Hickie
Journal:  Trials       Date:  2010-04-30       Impact factor: 2.279

5.  The generalized anxiety spectrum: prevalence, onset, course and outcome.

Authors:  Jules Angst; Alex Gamma; David S Baldwin; Vladeta Ajdacic-Gross; Wulf Rössler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06-24       Impact factor: 5.270

6.  [Comorbidity of major depression with other common mental disorders in primary care patients].

Authors:  Enric Aragonès; Josep Lluís Piñol; Antonio Labad
Journal:  Aten Primaria       Date:  2009-05-09       Impact factor: 1.137

7.  Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review.

Authors:  Boadie W Dunlop; Paula G Davis
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

8.  Comorbidity of generalized anxiety disorder and alcohol use disorders among individuals seeking outpatient substance abuse treatment.

Authors:  Joshua P Smith; Sarah W Book
Journal:  Addict Behav       Date:  2009-08-07       Impact factor: 3.913

9.  Cultural adaptation into Spanish of the generalized anxiety disorder-7 (GAD-7) scale as a screening tool.

Authors:  Javier García-Campayo; Enric Zamorano; Miguel A Ruiz; Antonio Pardo; María Pérez-Páramo; Vanessa López-Gómez; Olga Freire; Javier Rejas
Journal:  Health Qual Life Outcomes       Date:  2010-01-20       Impact factor: 3.186

10.  Broadening of Generalized Anxiety Disorders Definition Does not Affect the Response to Psychiatric Care: Findings from the Observational ADAN Study.

Authors:  Enrique Alvarez; Jose L Carrasco; José M Olivares; Vanessa López-Gómez; Inma Vilardaga; María Perez
Journal:  Clin Pract Epidemiol Ment Health       Date:  2012-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.